Posted on Nov 8, 2021
Regeneron COVID-19 antibody drug reduces infection risk 82% in clinical trial
899
22
9
10
10
0
Regeneron COVID-19 antibody drug reduces infection risk 82% in clinical trial
Maia Anderson - 2 hours ago Print | Email
Share Listen
TEXT
Regeneron said Nov. 8 that its COVID-19 antibody cocktail reduced the risk of contracting COVID-19 by 81.6 percent for eight months after administration in a phase 3 clinical trial.
During the eight-month follow-up period, Regeneron said there were no hospitalizations from COVID-19 infection among the people receiving the antibody cocktail, called REGEN-COV, and six in the placebo group.
"Today's new data demonstrate how a single dose of REGEN-COV can help protect people from COVID-19 for many months after administration," Myron Cohen, MD, director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, said in a news release.
The trial included people living in the same household as someone with a COVID-19 infection.
"In this trial, a single dose of REGEN-COV provided long-term protection against COVID-19, including times of particularly high risk from household exposure, and in the longer-term during ongoing broader exposure," George Yancopoulos, MD, PhD, Regeneron's president and chief scientific officer, said in the news release.
He added that the drug could be particularly useful for immunocompromised people, who may not get adequate protection from the virus from existing vaccines.
REGEN-COV is a combination of the monoclonal antibodies casirivimab and imdevimab. In November 2020, it received FDA emergency use authorization. The FDA revised its emergency use authorization July 30, allowing the treatment to be used as a postexposure prophylaxis for COVID-19 in individuals who are at high risk for progression to severe COVID-19.
Read the full news release here
Maia Anderson - 2 hours ago Print | Email
Share Listen
TEXT
Regeneron said Nov. 8 that its COVID-19 antibody cocktail reduced the risk of contracting COVID-19 by 81.6 percent for eight months after administration in a phase 3 clinical trial.
During the eight-month follow-up period, Regeneron said there were no hospitalizations from COVID-19 infection among the people receiving the antibody cocktail, called REGEN-COV, and six in the placebo group.
"Today's new data demonstrate how a single dose of REGEN-COV can help protect people from COVID-19 for many months after administration," Myron Cohen, MD, director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, said in a news release.
The trial included people living in the same household as someone with a COVID-19 infection.
"In this trial, a single dose of REGEN-COV provided long-term protection against COVID-19, including times of particularly high risk from household exposure, and in the longer-term during ongoing broader exposure," George Yancopoulos, MD, PhD, Regeneron's president and chief scientific officer, said in the news release.
He added that the drug could be particularly useful for immunocompromised people, who may not get adequate protection from the virus from existing vaccines.
REGEN-COV is a combination of the monoclonal antibodies casirivimab and imdevimab. In November 2020, it received FDA emergency use authorization. The FDA revised its emergency use authorization July 30, allowing the treatment to be used as a postexposure prophylaxis for COVID-19 in individuals who are at high risk for progression to severe COVID-19.
Read the full news release here
Regeneron COVID-19 antibody drug reduces infection risk 82% in clinical trial
Posted from beckershospitalreview.comPosted in these groups: 
Medicine
Coronavirus COVID19
Healthcare
Public HealthCenters for Disease Control and Prevention
Medicine Coronavirus COVID19 Healthcare Public HealthCenters for Disease Control and Prevention
Posted 3 y ago
Responses: 4
2
2
0
SO??? Best I remember was that Donnie's Regeneron treatment cost $650,00.00 tax payer bucks. I'm sure that the insurance companies will foot that. Sarcasm.
(2)
(0)
2
2
0
2
2
0
MAJ Ken Landgren
COL (Join to see) - We don't have metrics on the vaccines but they have to be dangerous. Were you able to pass the PTSD paper to others?
(1)
(0)
MAJ Ken Landgren
Thank you. That paper has helped people which tells me two things. There are many who have PTSD and need help; the paper can actually help some people heal significantly. For those reasons I try to deploy the paper. I wish my cause had more traction. COL (Join to see)
(0)
(0)
Read This Next
Continue with Facebook 
Continue with Google